 |
 |
 |
 |
 |
 |
 |
|
|||||||
|
Select Publications
Bunn PA Jr, Thatcher N. Systemic treatment for advanced (Stage IIIb/IV) non-small cell lung cancer: More treatment options; more things to consider. Conclusion. Oncologist 2008;13 Suppl 1:37-46. Abstract
Douillard J-Y et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: A randomized, open-label Phase III study (INTEREST). Proc 12th World Conference on Lung Cancer 2007;Abstract PRS-02.
Gridelli C et al. The role of bevacizumab in the treatment of non-small cell lung cancer: Current indications and future developments. Oncologist 2007;12(10):1183-93. Abstract
Herbst RS et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25(30):4743-50. Abstract
Herbst RS et al. TRIBUTE: A Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell
lung cancer. J Clin Oncol 2005a;23(25):5892-9. Abstract
Herbst RS et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005b;23(11):2544-55. Abstract
Manegold C et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. Proc ASCO 2007;Abstract LBA7514.
Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50. Abstract
Shepherd FA et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32. Abstract
Wakelee H et al. Optimal adjuvant therapy for non-small cell lung cancer — How to handle stage I disease. Oncologist 2007;12(3):331-7. Abstract
| Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Mark G Kris, MD
- Select publications
Roman Perez-Soler, MD
- Select publications
Julie R Brahmer, MD
- Select publications
Philip Bonomi, MD
- Select publications
Lung Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
